Passage Bio Inc
PASG6.640USD
-0.680-9.29%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
1.06MMarket Cap
LossP/E TTM
More Details of Passage Bio Inc Company
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Passage Bio Inc Info
Ticker SymbolPASG
Company namePassage Bio Inc
IPO dateFeb 28, 2020
CEOMr. William Chou, M.D.
Number of employees60
Security typeOrdinary Share
Fiscal year-endFeb 28
AddressOne Commerce Square
CityPHILADELPHIA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code19103
Phone12678660312
Websitehttps://www.passagebio.com/
Ticker SymbolPASG
IPO dateFeb 28, 2020
CEOMr. William Chou, M.D.
Company Executives of Passage Bio Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
2.06K
+54.84%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Mr. William Chou, M.D.
Mr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
400.00
--
Dr. Dolan Sondhi, Ph.D.
Dr. Dolan Sondhi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Mr. Edgar B. (Chip) Cale
Mr. Edgar B. (Chip) Cale
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Thomas Kassberg
Mr. Thomas Kassberg
Independent Director
Independent Director
--
--
Dr. Derrell D. Porter, M.D.
Dr. Derrell D. Porter, M.D.
Independent Director
Independent Director
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
2.06K
+54.84%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Mr. William Chou, M.D.
Mr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
400.00
--
Dr. Dolan Sondhi, Ph.D.
Dr. Dolan Sondhi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Mr. Edgar B. (Chip) Cale
Mr. Edgar B. (Chip) Cale
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Oct 15
Updated: Wed, Oct 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
19.62%
Vestal Point Capital, LP
9.60%
OrbiMed Advisors, LLC
4.17%
New Leaf Venture Partners LLC
3.93%
Erste Asset Management GmbH
3.86%
Other
58.82%
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
19.62%
Vestal Point Capital, LP
9.60%
OrbiMed Advisors, LLC
4.17%
New Leaf Venture Partners LLC
3.93%
Erste Asset Management GmbH
3.86%
Other
58.82%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.29%
Investment Advisor/Hedge Fund
13.03%
Hedge Fund
5.36%
Private Equity
4.17%
Venture Capital
4.02%
Bank and Trust
0.34%
Individual Investor
0.21%
Research Firm
0.17%
Other
44.42%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
96
1.76M
55.37%
-633.14K
2025Q2
109
1.78M
57.30%
-572.43K
2025Q1
121
37.08M
59.66%
-12.05M
2024Q4
131
38.35M
62.10%
-13.63M
2024Q3
149
39.39M
63.77%
-15.73M
2024Q2
167
41.02M
66.55%
-10.76M
2024Q1
221
41.04M
66.61%
-5.04M
2023Q4
238
33.41M
60.80%
-9.36M
2023Q3
262
42.61M
77.93%
-14.06M
2023Q2
273
43.59M
79.78%
-13.92M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lynx1 Capital Advisors LLC
623.70K
19.62%
+32.01K
+5.41%
Sep 15, 2025
Vestal Point Capital, LP
305.00K
9.6%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
132.47K
4.17%
-170.29K
-56.25%
Jul 23, 2025
New Leaf Venture Partners LLC
124.90K
3.93%
--
--
Jun 30, 2025
Erste Asset Management GmbH
122.79K
3.86%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
102.03K
3.21%
-1.55K
-1.50%
Jun 30, 2025
Tang Capital Management, LLC
75.00K
2.36%
--
--
Jun 30, 2025
Renaissance Technologies LLC
70.82K
2.23%
+306.00
+0.43%
Jun 30, 2025
Acadian Asset Management LLC
46.69K
1.47%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
27.24K
0.86%
-5.64K
-17.15%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
